-
公开(公告)号:US20210208145A1
公开(公告)日:2021-07-08
申请号:US17207165
申请日:2021-03-19
Applicant: Genentech, Inc.
Inventor: Luciana Lorena MOLINERO , Stephen CHUI , Roel FUNKE
IPC: G01N33/574 , A61K39/395 , A61P35/00
Abstract: The invention provides methods and compositions for diagnosing and treating locally advanced or metastatic breast cancer (e.g., TNBC). In some embodiments, the methods include determining the presence and/or expression level of one or more of PD-L1, CD8, and/or stromal tumor-infiltrating lymphocytes (sTILs). Provided herein are methods for identifying a patient suffering from a locally advanced or metastatic TNBC who is likely to respond to treatment with an anti-cancer therapy that includes a PD-1 axis binding antagonist (e.g., an anti-PD-L1 antibody (e.g., atezolizumab) or an anti-PD-1 antibody) and a taxane (e.g., nab-paclitaxel or paclitaxel). Also provided are methods of selecting a therapy for a patient suffering from a locally advanced or metastatic TNBC. Further provided are methods of treating a patient suffering from locally advanced or metastatic TNBC. In some embodiments, the methods include administering a PD-1 axis binding antagonist (e.g., atezolizumab) and a taxane (e.g., nab-paclitaxel or paclitaxel) to the patient, for example, a patient identified as one who is likely to respond to the treatment. Also provided are pharmaceutical compositions for use in treating a patient suffering from locally advanced or metastatic TNBC.
-
公开(公告)号:US20220016243A1
公开(公告)日:2022-01-20
申请号:US17159128
申请日:2021-01-26
Applicant: Genentech, Inc. , Hoffmann-La Roche Inc.
Inventor: Catherine LAI , Janet LAU , Anthony Jongha LEE , Shi LI , Yvonne Gail LIN-LIU , Christina Jeanne MATHENY , Diana MENDUS , Raymond D. MENG , Anh NGUYEN DUC , Jilpa Bhupendra PATEL , Thinh Quang PHAM , Isabelle Anne ROONEY , Heather Blythe STEVENS , Sarah Marie TROUTMAN , Lijia WANG , Yulei WANG , Patrick Georges Robert WILLIAMS , Benjamin WU , Yibing YAN , Aijing ZHANG , Xiaosong ZHANG , Marcus Dale BALLINGER , Hila BARAK , Elizabeth Alexandra BENNETT , Marcela Lucia CASTRO , Edward Namserk CHA , Hui Min Phyllis CHAN , Stephen CHUI , Christopher Roland COTTER , Viraj Vinay DEGAONKAR , Barbara Jennifer GITLITZ , Tien HOANG , Kimberly Mayumi KOMATSUBARA
IPC: A61K39/395 , A61P35/00 , A61K31/282 , A61K31/7048 , A61K31/519 , A61K31/7068 , A61K31/337 , A61K38/19 , A61K47/60 , A61K31/675 , A61P35/04 , A61K33/243 , A61K47/68 , A61K31/513 , C07K16/28
Abstract: The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a lung cancer; a cervical cancer; a breast cancer; a head and neck cancer; a liver cancer; a bladder cancer; a gastric cancer; an esophageal cancer; a pancreatic cancer; a kidney or renal cancer; a melanoma; an ovarian cancer; or a colorectal cancer). More specifically, the invention concerns the treatment of patients having cancer with an anti-TIGIT antagonist antibody, including treatment with an anti-TIGIT antagonist antibody in a combination therapy.
-
公开(公告)号:US20240424092A1
公开(公告)日:2024-12-26
申请号:US18754676
申请日:2024-06-26
Applicant: Genentech, Inc. , Hoffmann-La Roche Inc.
Inventor: Catherine LAI , Janet LAU , Anthony Jongha LEE , Shi LI , Yvonne Gail LIN-LIU , Christina Jeanne MATHENY , Diana MENDUS , Raymond D. MENG , Anh NGUYEN DUC , Jilpa Bhupendra PATEL , Thinh Quang PHAM , Isabelle Anne ROONEY , Heather Blythe STEVENS , Sarah Marie TROUTMAN , Lijia WANG , Yulei WANG , Patrick Georges Robert WILLIAMS , Benjamin WU , Yibing YAN , Aijing ZHANG , Xiaosong ZHANG , Marcus Dale BALLINGER , Hila BARAK , Elizabeth Alexandra BENNETT , Marcela Lucia CASTRO , Edward Namserk CHA , Hui Min Phyllis CHAN , Stephen CHUI , Christopher Roland COTTER , Viraj Vinay DEGAONKAR , Barbara Jennifer GITLITZ , Tien HOANG , Kimberly Mayumi KOMATSUBARA
IPC: A61K39/395 , A61K31/282 , A61K31/337 , A61K31/513 , A61K31/519 , A61K31/675 , A61K31/7048 , A61K31/7068 , A61K33/243 , A61K38/19 , A61K39/00 , A61K47/60 , A61K47/68 , A61P35/00 , A61P35/04 , C07K16/28
Abstract: The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a lung cancer; a cervical cancer; a breast cancer; a head and neck cancer; a liver cancer; a bladder cancer; a gastric cancer; an esophageal cancer; a pancreatic cancer; a kidney or renal cancer; a melanoma; an ovarian cancer; or a colorectal cancer). More specifically, the invention concerns the treatment of patients having cancer with an anti-TIGIT antagonist antibody, including treatment with an anti-TIGIT antagonist antibody in a combination therapy.
-
-